share_log

方盛制药(603998.SH)通过药品GMP符合性检查

Fangsheng Pharmaceutical (603998.SH) passed the drug GMP compliance inspection

Zhitong Finance ·  Apr 9 03:33

Fangsheng Pharmaceutical (603998.SH) issued an announcement. The company received the “Drug G...” issued by the Hunan Drug Administration

Zhitong Finance App News, Fangsheng Pharmaceutical (603998.SH) issued an announcement. The company received the “Drug GMP Compliance Inspection Notice” issued by the Hunan Drug Administration. The scope of inspection includes tablets (integrated solid three-workshop tablet production line 5) and hard capsules (integrated solid three-workshop hard capsule production line 4); cold antipyretic particles (Sinopharm standard Z41020991) (traditional Chinese medicine extraction workshop 1 traditional Chinese medicine pre-treatment and extraction production line, integrated solid one-workshop granule production line 1).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment